Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled Study to Determine Time to Onset of Suppression of the Bone Resorption Marker sCTX With Once Monthly Ibandronate in the Treatment of Postmenopausal Osteoporosis

NCT00303485 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT00303485
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00303485 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled Study to Determine Time to Onset of Suppression of the Bone Resorption Marker sCTX With Once Monthly Ibandronate in the Treatment of Postmenopausal Osteoporosis
Lead sponsor
Hoffmann-La Roche
Phase
Phase 4
Overall status
Completed
Start date
February 28, 2006
Completion date
June 30, 2007
Enrollment
67 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

post menopausal osteoporosis